SOURCE: LifeSci Advisors

LifeSci Advisors

February 12, 2014 09:00 ET

LifeSci Advisors Initiates Coverage of Kindred Biosciences, Inc.

Pivotal Data From 3 Lead Veterinary Medicine Programs Expected in 2014; Report Available for Download at

NEW YORK, NY--(Marketwired - Feb 12, 2014) -  LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on quickly and efficiently developing animal medicines for the growing pet therapeutics market. The Company identifies approved and validated human medications that can be repurposed to improve the lives and health of companion animals. The cost and time requirements necessary to bring animal drugs to market are substantially lower than for human medicines, allowing Kindred Bio to develop three lead drug candidates simultaneously. Pivotal data are expected for these programs in 2014 and potential New Animal Drug Applications (NADA) are also expected in 2014.

"Kindred Bio leverages existing human medicine data to develop animal treatments at a pace and cost that is unmatched in the biotechnology industry," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The rapid pace of development has allowed Kindred Bio to bring three lead candidates to the point of potential regulatory filings in 2014, and positions the Company at the forefront of the emerging pet therapeutics market."

Kindred Bio's most advanced candidate, CereKin®, is being tested in a pivotal trial to establish safety and efficacy in dogs. CereKin (diacerein) is an IL-1β inhibitor for the treatment of osteoarthritis which, like AtoKin®, is formulated as an oral, flavored, chewable pill. AtoKin® (fexofenadine) is a reformulated, high-dose version of fexofenadine for the treatment of atopic dermatitis, and a pivotal trial is expected to launch in 2014. SentiKin® is a non-opioid, non-NSAID, non-steroid for the treatment of postoperative pain in dogs, and is also expected to enter a pivotal trial in 2014. Kindred Bio has a portfolio of multiple additional product candidates in development, including biologics such as a canine version of Enbrel®.

In a 53 page Initiation Report by LifeSci Advisors, we explain the data supporting each drug candidate both in humans and animals. The report discusses the target indications for the lead programs in detail and the potential competitive advantages for Kindred Bio's candidates. We also explore the landscape and growth potential of the pet therapeutics and animal health space.

Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:

LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website,

Important Disclosures:

The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.

Contact Information